Novo Nordisk to cut 9,000 jobs: Ozempic maker to reduce workforce by 11%; refocus on diabetes and obesity treatments
Danish pharmaceutical giant Novo Nordisk on Wednesday announced plans to reduce its global workforce by 11 percent, eliminating 9,000 positions, including 5,000 in Denmark. The move aims to save eight billion kroner ($1.3 billion) as competition intensifies for its anti-obesity treatments Ozempic and Wegovy, as reported by AFP.The company also lowered its earnings forecast for…